How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Mass Spec Grade Lys-C Market
- By Product Form: Lyophilized Powder, Liquid Solution, Ready-to-use Kits
- By Purity Grade: Mass Spectrometry Grade, Sequencing Grade, Proteomics Grade
- By Application: Proteomics Research, Biopharmaceutical Development, Clinical Diagnostics, Food Safety Testing, Environmental Analysis
- By End-user: Academic and Government Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Clinical Laboratories
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Lyophilized Powder leads By Product Form at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 268 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.162 →
- 11 Company Profiles 14 players: SWOT & benchmarking p.170 →
Full report · locked preview
Everything inside the Mass Spec Grade Lys-C Market report
A complete, evidence-based study - 11 chapters and 112 sections covering market size, segmentation across 4 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Product Form 3
Purity Grade 3
Application 5
End-user 4
Companies profiled
Thermo Fisher Scientific
Merck KGaA (MilliporeSigma)
Promega Corporation
New England Biolabs (NEB)
Pierce Biotechnology (part of Thermo Fisher Scientific)
Agilent Technologies
Bio-Rad Laboratories
Waters Corporation
Sigma-Aldrich (part of Merck)
Protea Biosciences
AnaSpec (part of BioVision)
GenScript
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Merck KGaA (MilliporeSigma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Promega Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →New England Biolabs (NEB)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Pierce Biotechnology (part of Thermo Fisher Scientific)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bio-Rad Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Waters Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sigma-Aldrich (part of Merck)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Protea Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →AnaSpec (part of BioVision)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →GenScript
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Creative Proteomics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bachem
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,672M by 2033 · 4.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Lyophilized Powder63.8
- Liquid Solution20.3
- Ready-to-use Kits15.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,744M → $2,478M · 4.5%
Europe$1,215M → $1,952M · 6.1%
Asia Pacific$1,110M → $1,476M · 3.6%
Latin America$686.9M → $1,053M · 5.5%
Middle East and Africa$528.4M → $830.2M · 5.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.732026
4.732027
4.742028
4.772029
4.772030
4.792031
4.792032
4.802033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific11.2
- Merck KGaA (MilliporeSigma)26.1
- Promega Corporation5.6
- New England Biolabs (NEB)9.0
- Pierce Biotechnology (part of Thermo Fisher Scientific)7.2
- Agilent Technologies12.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Form16.4%
Purity Grade27.4%
Application30.0%
End-user26.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.8
- Europe25.1
- Asia Pacific18.9
- Latin America13.5
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 79 | 80 | 97 | 82 | 97 | 96 | 89 |
| Merck KGaA (MilliporeSigma) | 82 | 75 | 90 | 79 | 71 | 92 | 82 |
| Promega Corporation | 77 | 70 | 71 | 86 | 84 | 77 | 78 |
| New England Biolabs (NEB) | 81 | 71 | 82 | 71 | 70 | 82 | 76 |
| Pierce Biotechnology (part of Thermo Fisher Scientific) | 75 | 57 | 76 | 73 | 66 | 51 | 66 |
| Agilent Technologies | 70 | 71 | 60 | 49 | 68 | 70 | 65 |
| Bio-Rad Laboratories | 53 | 47 | 46 | 62 | 55 | 47 | 52 |
| Waters Corporation | 57 | 52 | 47 | 40 | 51 | 42 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Merck KGaA (MilliporeSigma)
- Promega Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Merck KGaA (MilliporeSigma) | ✓ | ◐ | ✓ | ◐ | − | ✓ |
| Promega Corporation | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| New England Biolabs (NEB) | ◐ | ◐ | ✓ | ◐ | ✓ | ✓ |
| Pierce Biotechnology (part of Thermo Fisher Scientific) | ◐ | − | ✓ | ✓ | ◐ | ◐ |
| Agilent Technologies | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Bio-Rad Laboratories | − | ◐ | − | ◐ | − | ◐ |
| Waters Corporation | ◐ | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific89
2Merck KGaA (MilliporeSigma)82
3Promega Corporation78
4New England Biolabs (NEB)76
5Pierce Biotechnology (part of Thermo Fisher Scientific)66
6Agilent Technologies65
7Bio-Rad Laboratories52
8Waters Corporation48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificMerck KGaA (MilliporeSigma)Promega Corporation
Challenger1
Strong scale, closing on the leaders.
New England Biolabs (NEB)
Contender2
Focused players with pockets of strength.
Pierce Biotechnology (part of Thermo Fisher Scientific)Agilent Technologies
Niche2
Specialists in a single segment or region.
Bio-Rad LaboratoriesWaters Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Form in North America, then scale across Mass Spec Grade Lys-C Market — a $344M beachhead inside a $6.12B market.
Beachhead (SOM)$344Mobtainable near-term
Serviceable (SAM)$2.17Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Lyophilized Powder
Best fit — highest urgency & budget in Product Form.
Economic buyer78 fit
Liquid Solution
Strong fit — clear ROI and a fast path to value.
End user66 fit
Ready-to-use Kits
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Form in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Purity Grade & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel28%
Digital / self-serve23%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Form leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Mass Spec Grade Lys-C Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation13%
Closed-won7%
$18.5KCAC
$76KLTV
4.1:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Mass Spec Grade Lys-C Market is a high-growth opportunity — $5.16B by 2033, compounding at 11.2%.
TAM · 2025$2.20Btoday
TAM · 2033$5.16Bforecast
CAGR11.2%2027–2033
Cumulative$31.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.16BTotal addressable market
SAM$1.91BServiceable available market
SOM$413MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.2% CAGR
Demand compounds through 2033, outpacing GDP across Product Form.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Form moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.16BLarge & growingTAM by 2033 at 11.2% CAGR
$1.91BServiceable nowreachable with today’s model
$413MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.02BBear7.3% CAGR
$5.16BBase11.2% CAGR
$6.60BBull14.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Purity Grade optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Mass Spec Grade Lys-C Market — a $2.56B market by 2033. Plan: grow share from 9.8% to 15.5%.
Market size · 2033$2.56Btotal addressable
Market CAGR9.0%2027–2033
Target share15.5%from 9.8% today
Revenue ambition$397Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.8% | 15.5% | On track |
| Revenue | $233M | $397M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.5% | 39.4% | Behind |
| Customer retention | 85.0% | 94.6% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Form
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Purity Grade capability
A defensible second engine — invest in Purity Grade to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Form share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Purity Grade
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $40M capacity & capability investment
- Greenlight bolt-on M&A in Purity Grade
- Authorise North America expansion plan
- Fund R&D program for Product Form leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Mass Spec Grade Lys-C Market conversation — a $812M market you can size, segment and defend in minutes.
Market size · 2033$812Mtotal opportunity
Growth6.9%CAGR to 2033
Addressable buyers1,172+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Form
Goal Grow share in Product Form
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 2 mopayback period
$80K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Thermo Fisher ScientificMerck KGaA (MilliporeSigma)Promega CorporationNew England Biolabs (NEB)Pierce Biotechnology (part of Thermo Fisher Scientific)Agilent TechnologiesBio-Rad LaboratoriesWaters Corporation+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Mass Spec Grade Lys-C Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Mass Spec Grade Lys-C Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Mass Photometer Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportMass Pectrograph Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportMassive Machine Type Communication in Healthcare Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportMassage Therapy Services Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportMassage Therapy Bed Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportMassager Gun Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportMassage Intermittent Air Pump Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportMassage Fascia Gun Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportMassage Device Market
Market size, share, segmentation and regional forecast.
$317M market · 2025 base year
View reportMassage Balls Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportMask Vending Machine Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportMask UV Sterilizers Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.